Home Innovation That Matters

Innovation That Matters

Inside Perspectives on Gene Editing: An Interview with Agenovir CEO Dirk Thye

Using its deep virology expertise and targeted genome editing technologies, Agenovir is on a mission to develop novel antiviral therapeutics, bringing hope to millions of patients who suffer from devastating, persistent viral infections. In particular, the South San Francisco start-up is using CRISPR-Cas9 technology to create topical...

Idea Factory: From the Classroom to the Lab, Robert Langer’s Impact is Felt Around the Globe

By Rich Soll, Senior Vice President, Research Service Division, WuXi AppTec (@richsollwx) Known as the “Thomas Edison of Biomedicine," professor Robert Langer is one of the most highly cited individuals in history, and founder of more than 40 biotech companies. While he is widely regarded...

Funding “Crazy” Ideas; Building Extraordinary Companies

By Hui Cai, Vice President of Corporate Alliances and Head of Corporate Communications, WuXi AppTec Kristina Burow has a knack for spotting big ideas in biotech. In fact, the seasoned investor and trained Scripps Research Institute chemist has helped pave a successful path for many...

Celgene’s Bold Approach to Creating Next Generation Therapeutics

By Rich Soll, Senior Vice President, Research Service Division, WuXi AppTec (@richsollwx) With its innovative pipeline of products and distinct approach to R&D, Celgene may have found the industry’s secret sauce to growth and sustainability. Key drivers of that is the three decades-old biopharmaceutical company’s...

Inside Perspectives: Will Immunotherapy Knock Out Cancer?

The answer is yes, and no. Advances in just the past five years have proven immunotherapy can stimulate the immune system’s natural capabilities to kill cancer cells, and possibly lead to cures for many patients. So yes, it appears immunotherapy is the best weapon yet...

SPOTLIGHT

STAY CONNECTED

Twitter LinkedIn 

WUXI NEWS

The U.S. FDA Completed Pre-License Inspection (PLI) of WuXi Biologics CGMP...

We are pleased to announce that the U.S. Food and Drug Administration has completed the Pre-License Inspection (PLI) of WuXi Biologics cGMP manufacturing facilities...